Covance Receives AAALAC Accreditation for Early Development Facility in Chandler
PRINCETON, N.J., Oct 26, 2009 /PRNewswire-FirstCall via COMTEX/ -- Covance Inc. (NYSE: CVD) today announced that the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) awarded full accreditation to the company's state-of-the-art early development research facility in Chandler, Arizona.
Promoting the humane treatment of animals in science worldwide through voluntary accreditation and assessment programs, AAALAC International recognizes the highest standards for animal care and use in 31 countries.
"We are pleased to receive unanimous approval from AAALAC International for full accreditation with no additional recommendations for improvement," said Monique Heiser-Wong, vice president and general manager, Covance. "The Council on Accreditation of AAALAC International commended the management and staff at the Chandler facility for providing institutional and administrative commitment to the animal care program as evidenced by our newest facility, equipment, and programs."
AAALAC International endorses the ethical use of animals to advance medicine and science when alternatives are not available. Voluntary accreditation and assessment is designed to recognize research programs that demonstrate excellence in animal care and use.
"Covance is proud to increase its global footprint in North America and to now offer premium early drug development services at a West Coast facility," said Mike Lehmann, president, non-clinical safety assessment services, Covance. "AAALAC accreditation demonstrates Covance's commitment to deliver the highest levels of quality to our global clients - in both data quality and animal care."
Covance's 288,000-square-foot facility in Chandler opened in 2009 to provide state-of-the-art preclinical safety testing services, including GLP toxicology and bioanalytical services. Covance offers a complete range of toxicology services and safety assessment services, including standard and specialized services, to help pharmaceutical and biotechnology companies achieve study goals quickly and with greater confidence.
Covance, with headquarters in Princeton, NJ, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 25 countries, and more than 10,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.